Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 9k
23 March 2020
E-001789/2020
Question for written answer E-001789/2020
to the Commission
Rule 138
Miroslav Číž (S&D)
 Answer in writing 
 Subject: The EU’s pharmaceutical strategy

Once the coronavirus is over, the EU will need policies not only to foster research, but also to ensure patients’ access to medicines in the most sustainable way possible. It is clear that as a result of the most recent developments, the discussion on the EU’s pharmaceutical strategy is expected to gain in importance in the eyes of the public.

How does the Commission intend to handle this pressure and is there any timetable that we might be able to follow?

In order to cope with crises like these, the EU needs to manage its healthcare systems more broadly. Against this backdrop, what are the next steps the Commission will take to ensure more support for research and more sustainable health systems?

Last updated: 25 September 2020Legal notice - Privacy policy